Fully liquid Hib-DTP-hepatitis-B vaccine - LG Life Sciences

Drug Profile

Fully liquid Hib-DTP-hepatitis-B vaccine - LG Life Sciences

Alternative Names: DTwP-HepB-Hib (Fully liquid); Eupenta; Fully liquid pentavalent vaccine, Diphtheria-Tetanus-whole cell Pertussis-Hepatitis B-Haemophilus influenzae type b (tetanus toxoid conjugate) - LG Life Sciences; LBVP0101-01

Latest Information Update: 08 Oct 2015

Price : $50

At a glance

  • Originator LG Life Sciences
  • Class Haemophilus vaccines; Hepatitis B vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Tetanus

Most Recent Events

  • 28 Aug 2015 Preclinical trials in Tetanus (In infants, Prevention) in China (IM)
  • 28 Aug 2015 Preclinical trials in Pertussis (In infants, Prevention) in China (IM)
  • 28 Aug 2015 Preclinical trials in Hepatitis B (In infants, Prevention) in China (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top